| Systematic (IUPAC) name | |
|---|---|
| rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17- | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 199396-76-4 |
| ATC code | None |
| PubChem | CID 9577221 |
| IUPHAR ligand | 2883 |
| ChemSpider | 7851660 |
| UNII | 72W09924WP |
| KEGG | D02996 |
| ChEMBL | CHEMBL267431 |
| Chemical data | |
| Formula | C28H35NO4 |
| Mol. mass | 449.582 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone sensitive myomata.[1]
In 2005, Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed.[2]
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)